REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2020

Aug 31, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS, INC. (REGN)
CIK: 0000872589
Period of Report: 2020-08-27

Reporting Person: LAROSA JOSEPH J (EVP General Counsel and Secret)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-08-27	Common Stock	M	6000	$52.03	Acquired	20438	Direct
2020-08-27	Common Stock	F	3197	$614.87	Disposed	17241	Direct
2020-08-27	Common Stock	M	4000	$52.03	Acquired	21241	Direct
2020-08-27	Common Stock	F	2131	$614.87	Disposed	19110	Direct
2020-08-31	Common Stock	S	4672	$615.04	Disposed	14438	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-08-27	Non-Qualified Stock Option (right to buy)	$52.03	M	6000	Disposed	2021-12-16	Common Stock (6000)	Direct
2020-08-27	Non-Qualified Stock Option (right to buy)	$52.03	M	4000	Disposed	2021-12-16	Common Stock (4000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	287	Indirect

Footnotes

F1: Represents volume-weighted average price of sales of 4,672 shares of Company stock on August 31, 2020 at prices ranging from $615.00 to $615.40. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 31, 2020 at each separate price.

F2: With respect to 6,000 underlying shares (of which 0 remain outstanding), the option became exercisable on December 31, 2014, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2014. With respect to 4,000 underlying shares (of which 0 remain outstanding), the stock option award vested in four equal annual installments, commencing one year after the date of grant.